Please Wait.....
Report
Clinical Trials Market Assessment, By Phase [Phase I, Phase II, Phase III, and Phase IV], By Service Type [Laboratory Services, Bioanalytical and Analytical Testing Services, Patient Recruitment and Site Identification, Clinical Trial Data Management Services, Protocol Designing, Medical Device Testing Services, Other Services], By Therapeutic Area [Oncology, Cardiology, Neurology, Infectious Diseases, Other Therapeutic Areas], By Application [Small Molecules, Vaccines, Cell and Gene Therapies, Monoclonal Antibodies, Other Applications], By Study Designs Outlook [Interventional, Observational, Expanded Access], By Sponsor Type [Pharmaceutical Companies, Medical Devices Companies, Academic Institutes], By Region, Opportunities and Forecast, 2017-2031F
Market Report I 2024-09-30 I 246 Pages I Market Xcel - Markets and Data
Global clinical trials market is projected to witness a CAGR of 7.17% during the forecast period 2024-2031, growing from USD 62.38 billion in 2023 to USD 108.55 billion in 2031. The growth of the clinical trials market is expected to be driven by higher R&D investments from pharmaceutical companies coupled with rising focus on rare and orphan disease treatment. These elements will create a strong need for innovative research and new treatments, further driving the market growth.
The global clinical trials market is experiencing substantial growth, fueled by increased investments in research and development from pharmaceutical companies. The growing prevalence of both chronic and new diseases like Nipah virus infection and Lassa fever is boosting the demand for innovative treatments. Emerging markets are becoming crucial due to their cost-effectiveness and varied patient demographics. Moreover, there is a heightened emphasis on rare diseases and orphan drugs, backed by regulatory incentives that encourage their development. The advent of digital health technologies, including telemedicine and wearable devices, is improving trial efficiency and enhancing patient engagement. For instance, in November 2023, AstraZeneca PLC introduced a new initiative called Evinova, aimed at enhancing clinical trials through digital solutions that boost efficiency and cut costs. This development is supported by ongoing technological advancements and evolving regulatory conditions.
Rising Investments in R&D to Boost Market Growth
The global clinical trials market is growing rapidly, driven by increased R&D investments across pharmaceuticals, medical devices, biotechnology, and healthcare IT. Companies such as ICON plc, Biogen Inc., Novartis AG, and F. Hoffmann-La Roche AG are at the forefront, advancing innovation and expanding clinical research capabilities. Their contributions highlight the sector's dynamic evolution and expansion. In addition, the inclusion of health technologies such as telemedicine and wearable devices is accelerating the trial process and enhancing patient engagement. For instance, Accenture PLC's strategic investment in QuantHealth Ltd., a company that uses AI to simulate clinical trials in the cloud, demonstrates how R&D funding speeds up the development of treatments, making the process quicker and more cost-effective. These initiatives highlight the significant influence of rising R&D investment on the progress of the clinical trials market.
Increasing Demand for Advanced Treatments Drives Market Growth
Rising demand for novel treatment is a major factor propelling the growth of the clinical trials market. With patients and healthcare professionals demanding better approaches to care, pharmaceutical and biotech organizations are funding significant amounts towards the clinical research world to meet these demands. And that is driving an acceleration of the start-up phase for new clinical trials and exploration of newer drug compounds. For instance, in February 2024, IOVANCE Biotherapeutics, Inc. has received the United States FDA's approval for Amtagvi, a novel cancer therapy - tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi is designed for metastatic melanoma patients who are not eligible for other treatment options. The treatment works by enhancing immune cells within tumors to improve their cancer-fighting capabilities. This development showcases how the pursuit of cutting-edge treatments drives the growth of the clinical trials market, encouraging the creation of innovative therapies and specialized trial services.
Dominance of Phase II Clinical Trial
Phase II clinical trials play a vital role in the growth of the global clinical trials market by evaluating the effectiveness of new treatments on a broader scale. The complexity of these trials drives the demand for advanced services and technologies, increasing the need for specialized management and data analysis. When successful, these trials can lead to faster regulatory approvals and attract additional investment. The larger patient populations involved enhance recruitment and engagement efforts. For instance, as per ClinicalTrials.gov, there are around 94,000 active clinical trials in the field of cancer, of which around 30,000 trials are in Phase II, accounting for 31% of the total ongoing trials as of August 2024.
North America Dominates the Global Clinical Trials Market
North America leads the clinical trials market due to its effective regulatory framework, substantial financial resources, cutting-edge research infrastructure, diverse patient populations, operational excellence, political and economic stability, and a strong focus on innovation and collaboration. These factors collectively establish an optimal environment for conducting high-quality clinical trials, reinforcing North America's pivotal role in advancing global medical research and development. There has been a significant change in the distribution of clinical trials by region. Over the past five years, there was a steady rise in the number of newly recruiting trials' registration in the North America region. According to the WHO data, as of 2022, 168,520 clinical trials were registered in the United States; while 34,041 clinical trials were conducted in Canada.
Future Market Scenario (2024-2031F)
The clinical trials market is poised for impressive gains with the burgeoning trend of personalized medicine which encompasses treatments that are developed specifically for patients based on their genetic profiles and biomarkers. This strategy supports new types of clinical trials, such as adaptive and basket trials, which save costs by being more efficient. Aligning trials with the needs of patients also supports patient recruitment and retention, improving data quality to produce better outcomes. The use of advanced technologies and genomic data will further streamline trials, while supportive regulatory frameworks will speed up approvals. For instance, GSK plc's collaboration with Tempus exemplifies this trend, as GSK utilizes Tempus' AI-driven platform and patient data to enhance trial design, accelerate enrolment, and identify drug targets, boosting R&D success and expediting personalized treatment delivery.
Key Players Landscape and Outlook
Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., IQVIA, Inc., Laboratory Corporation of America Holdings, Caidya, ICON plc, Medpace Holdings, Inc., Parexel International Corporation, SGS Societe Generale de Surveillance SA, and Fortrea Inc., among others, are some of the leading companies in the clinical trials market, generating the highest revenue from drugs sales recently. The global clinical trials market is competitive, with a huge number of players operating in the local markets as well. Regulatory approvals of company products, mergers and acquisitions, and collaborations are the most common market strategies that have been observed in recent times.
- In February 2024, Medidata, a Dassault Systemes company specializing in clinical trial solutions, renewed its partnership with the PPD clinical research business of Thermo Fisher Scientific Inc. The renewed agreement includes the Medidata Platform, Medidata Adjudicate, and additional Medidata Rave products. This collaboration aims to enhance the PPD clinical research business's capabilities in supporting its clients' drug development programs, further advancing clinical trial processes and efficiency.
- In September 2023, the US Biomedical Advanced Research and Development Authority (BARDA) partnered with Ireland-based ICON plc to advance COVID-19 vaccine trials under the "Project NextGen" initiative. This project, part of BARDA's Strategic Preparedness and Response division, aims to develop vaccines and therapies for current and future COVID-19 strains. The initiative reflects BARDA's commitment to public-private partnerships, with over USD 5 billion allocated to bolster pandemic preparedness and response.
1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Global Clinical Trials Market Outlook, 2017-2031F
4.1. Market Size Analysis & Forecast
4.1.1. By Value
4.2. Market Share Analysis & Forecast
4.2.1. By Phase
4.2.1.1. Phase I
4.2.1.2. Phase II
4.2.1.3. Phase III
4.2.1.4. Phase IV
4.2.2. By Service Type
4.2.2.1. Laboratory Services
4.2.2.2. Bioanalytical and Analytical Testing Services
4.2.2.3. Patient Recruitment and Site Identification
4.2.2.4. Clinical Trial Data Management Services
4.2.2.5. Protocol Designing
4.2.2.6. Medical Device Testing Services
4.2.2.7. Other Services
4.2.3. By Therapeutic Area
4.2.3.1. Oncology
4.2.3.2. Cardiology
4.2.3.3. Neurology
4.2.3.4. Infectious Diseases
4.2.3.5. Other Therapeutic Areas
4.2.4. By Application
4.2.4.1. Small Molecules
4.2.4.2. Vaccines
4.2.4.3. Cell & Gene Therapies
4.2.4.4. Monoclonal Antibodies
4.2.4.5. Other Applications
4.2.5. By Study Design Outlook
4.2.5.1. Interventional
4.2.5.2. Observational
4.2.5.3. Expanded Access
4.2.6. By Sponsor Type
4.2.6.1. Pharmaceutical Companies
4.2.6.2. Medical Device Companies
4.2.6.3. Academic Institutes
4.2.7. By Region
4.2.7.1. North America
4.2.7.2. Europe
4.2.7.3. Asia-Pacific
4.2.7.4. South America
4.2.7.5. Middle East and Africa
4.2.8. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
4.3.1. By Phase
4.3.2. By Service Type
4.3.3. By Therapeutic Area
4.3.4. By Application
4.3.5. By Study Design Outlook
4.3.6. By Sponsor Type
4.3.7. By Region
5. North America Clinical Trials Market Outlook, 2017-2031F*
5.1. Market Size Analysis & Forecast
5.1.1. By Value
5.2. Market Share Analysis & Forecast
5.2.1. By Phase
5.2.1.1. Phase I
5.2.1.2. Phase II
5.2.1.3. Phase III
5.2.1.4. Phase IV
5.2.2. By Service Type
5.2.2.1. Laboratory Services
5.2.2.2. Bioanalytical and Analytical Testing Services
5.2.2.3. Patient Recruitment and Site Identification
5.2.2.4. Clinical Trial Data Management Services
5.2.2.5. Protocol Designing
5.2.2.6. Medical Device Testing Services
5.2.2.7. Other Services
5.2.3. By Therapeutic Area
5.2.3.1. Oncology
5.2.3.2. Cardiology
5.2.3.3. Neurology
5.2.3.4. Infectious Diseases
5.2.3.5. Other Therapeutic Areas
5.2.4. By Application
5.2.4.1. Small Molecules
5.2.4.2. Vaccines
5.2.4.3. Cell & Gene Therapies
5.2.4.4. Monoclonal Antibodies
5.2.4.5. Other Applications
5.2.5. By Study Design Outlook
5.2.5.1. Interventional
5.2.5.2. Observational
5.2.5.3. Expanded Access
5.2.6. By Sponsor Type
5.2.6.1. Pharmaceutical Companies
5.2.6.2. Medical Device Companies
5.2.6.3. Academic Institutes
5.2.7. By Country Share
5.2.7.1. United States
5.2.7.2. Canada
5.2.7.3. Mexico
5.3. Country Market Assessment
5.3.1. United States Clinical Trials Market Outlook, 2017-2031F*
5.3.1.1. Market Size Analysis & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share Analysis & Forecast
5.3.1.2.1. By Phase
5.3.1.2.1.1. Phase I
5.3.1.2.1.2. Phase II
5.3.1.2.1.3. Phase III
5.3.1.2.1.4. Phase IV
5.3.1.2.2. By Service Type
5.3.1.2.2.1. Laboratory Services
5.3.1.2.2.2. Bioanalytical and Analytical Testing Services
5.3.1.2.2.3. Patient Recruitment and Site Identification
5.3.1.2.2.4. Clinical Trial Data Management Services
5.3.1.2.2.5. Protocol Designing
5.3.1.2.2.6. Medical Device Testing Services
5.3.1.2.2.7. Other Services
5.3.1.2.3. By Therapeutic Area
5.3.1.2.3.1. Oncology
5.3.1.2.3.2. Cardiology
5.3.1.2.3.3. Neurology
5.3.1.2.3.4. Infectious Diseases
5.3.1.2.3.5. Other Therapeutic Areas
5.3.1.2.4. By Application
5.3.1.2.4.1. Small Molecules
5.3.1.2.4.2. Vaccines
5.3.1.2.4.3. Cell & Gene Therapies
5.3.1.2.4.4. Monoclonal Antibodies
5.3.1.2.4.5. Other Applications
5.3.1.2.5. By Study Design Outlook
5.3.1.2.5.1. Interventional
5.3.1.2.5.2. Observational
5.3.1.2.5.3. Expanded Access
5.3.1.2.6. By Sponsor Type
5.3.1.2.6.1. Pharmaceutical Companies
5.3.1.2.6.2. Medical Device Companies
5.3.1.2.6.3. Academic Institutes
5.3.2. Canada
5.3.3. Mexico
*All segments will be provided for all regions and countries covered
6. Europe Clinical Trials Market Outlook, 2017-2031F
6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland
7. Asia-Pacific Clinical Trials Market Outlook, 2017-2031F
7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines
8. South America Clinical Trials Market Outlook, 2017-2031F
8.1. Brazil
8.2. Argentina
9. Middle East and Africa Clinical Trials Market Outlook, 2017-2031F
9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel
10. Porter's Five Forces Analysis
11. Market Dynamics
11.1. Market Drivers
11.2. Market Challenges
12. Market Trends and Developments
13. Regulatory Framework and Innovation
13.1. Clinical Trials
14. Case Studies
15. Competitive Landscape
15.1. Competition Matrix of Top 5 Market Leaders
15.2. SWOT Analysis for Top 5 Players
15.3. Key Players Landscape for Top 10 Market Players
15.3.1. Thermo Fisher Scientific Inc.
15.3.1.1. Company Details
15.3.1.2. Key Management Personnel
15.3.1.3. Products and Services
15.3.1.4. Financials (As Reported)
15.3.1.5. Key Market Focus and Geographical Presence
15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
15.3.2. Novo Nordisk A/S
15.3.3. IQVIA, Inc.
15.3.4. Laboratory Corporation of America Holdings
15.3.5. Caidya
15.3.6. ICON plc
15.3.7. Medpace Holdings, Inc.
15.3.8. Parexel International Corporation
15.3.9. Charles River Laboratories International, Inc.
15.3.10. SGS Societe Generale de Surveillance SA
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
16. Strategic Recommendations
17. About Us and Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security